Clinical application for new indications of treatment of pulmonary infarction with recombinant human urokinase for injection by tisley has been accepted

According to the company, the application process for adding new indications is no less than that for new drugs After the clinical trial is completed, it needs to be submitted for certification, which is expected to take a long time Recombinant human urokinase for injection was developed jointly by Shanghai Tianshili Pharmaceutical Co., Ltd., a subsidiary of Tianshili, and the Institute of bioengineering, Academy of Military Medical Sciences of the people's Liberation Army It was approved to be listed in 2011 and used clinically for thrombolytic therapy of acute ST segment elevation myocardial infarction It is the first class 1 new biological product for major new drug creation science and technology in the 11th Five Year Plan period in China It is Tianshili Exclusive products of Shili According to the public data, pulmonary infarction is the necrosis of lung tissue caused by the blockage of blood flow after pulmonary embolism, and the common embolus causing pulmonary embolism is deep vein thrombosis About 10-15% of pulmonary embolism will lead to pulmonary infarction, which has the characteristics of sudden onset, ferocity, critical condition and high mortality According to the autopsy data of more than 900 cases of cardiopulmonary vascular disease reported by Fuwai Hospital, 100 cases (11%) of large thrombus above the pulmonary segment were blocked Pulmonary embolism is a common complication of cardiopulmonary vascular disease Tianshili is a leading enterprise of modern Chinese medicine in China In 2013, the company's industrial business realized an operating revenue of 4.92 billion yuan Recombinant human urokinase for injection is a potential product of the company UBS Securities expects the sales revenue of the product will exceed 10 million this year.